Clinical trial NCT05968612: Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets
Official title: A Single-Dose, Bioequivalence and Food Effect Bioavailability Study in Healthy Volunteers Comparing the Commercial Lumacaftor 200 mg / Ivacaftor 125 mg Combination Film-Coated Tablet (Orkambi®) to the Lumacaftor 200 mg Film-Coated Tablet Formulation, and the Lumacaftor 200 mg Film-Coated Tablet Formulation in the Fasted to Fed State.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteer
Keywords: lumacaftor
cystic fibrosis transmembrane regulator-corrector
CFTR-corrector
food effect
healthy volunteers
cerebral blood flow
CBF
Lead sponsor: Qanatpharma Canada LTD
Sponsor class: INDUSTRY
First posted: 2023-08-01
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The objective of this study is to assess bioequivalence of lumacaftor from Lumacaftor 200 mg Film-Coated Tablet Formulation (Qanatpharma) versus the reference commercial product, Lumacaftor 200 mg /Ivacaftor 125 mg Combination Film-Coated Tablet (Orkambi®) in the fed state, and food-effect bioavailability of Lumacaftor 200 mg Film-Coated Tablet Formulation (Qanatpharma) in the fasted and fed state in healthy, non-smoking, male and non-pregnant female volunteers, 18 to 55 years of age, inclusive.

Detailed description: This single-dose, randomized, open-label, three-way crossover, three-period, three-sequence, three-treatment, single-centre, bioequivalence and food-effect study will compare lumacaftor from Lumacaftor 200 mg Film-Coated Tablet test formulation and the commercial product, Lumacaftor 200 mg/Ivacaftor 125 mg Combination Film-Coated Tablet (Orkambi®) under fed conditions, and food-effect bioavailability study of Lumacaftor 200 mg Film-Coated Tablet test formulation from fasted to fed state.

The products will be studied using a crossover design with 39 healthy, non-smoking male and non-pregnant female volunteers being administered an oral dose of 1 x (2 x lumacaftor 200 mg) under fasted and fed conditions and 1 x (2 x lumacaftor 200 mg/ ivacaftor 125 mg) under fed conditions. There will be at least a 14-day washout period between the study periods to avoid carry-over effects of the preceding treatments.

This study is being conducted to support development of a lumacaftor mono-substance treatment for improving cerebral blood flow.

Eligibility criteria: Inclusion Criteria:

1. Healthy, non-smoking male and non-pregnant female volunteers, 18 years to 55 years of age, inclusive.
2. Body mass index (BMI) that is between 18.5 and 30.0 kg/m\^2, inclusive.
3. Results of clinical laboratory tests are within the normal range or with a deviation that is not considered clinically significant by the principal investigator.
4. Ability to fast for at least 10 hours and consume a high-fat, high-calorie meal, as well as standard meals.
5. Agree not to have a tattoo or body piercing until the end of the study.
6. Agree not to receive the COVID-19 vaccination from 7 days prior to the first study drug dose until 7 days after the last study drug administration in the study.
7. Female subjects of childbearing potential and males who are able to father children must meet the criteria defined in the protocol.

Exclusion Criteria:

1. Known history or presence of any clinically significant diseases or conditions unless determined as not clinically significant by the Investigator.
2. Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the Investigator.
3. Presence of any significant physical or organ abnormality as determined by the Investigator.
4. A positive test result for any of the following: HIV, Hepatitis B surface antigen, Hepatitis C, drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), alcohol breath test and cotinine. Positive pregnancy test for female subjects.
5. Known history or presence of:

   * Alcohol abuse or dependence within one year prior to first drug administration;
   * Drug abuse or dependence;
   * Hypersensitivity or idiosyncratic reaction to lumacaftor and ivacaftor, its excipients, and/or related substances;
   * Food allergies
   * Presence of any dietary restrictions unless deemed by the Investigator as "Not Clinically Significant".
   * Severe allergic reactions (e.g. anaphylactic reactions, angioedema).
6. Intolerance to and/or difficulty with blood sampling through venipuncture.
7. Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets, etc.
8. Individuals who have donated, in the days prior to first study drug administration:

   * 50-499 mL of blood in the previous 30 days;
   * 500 mL or more in the previous 56 days.
9. Donation of plasma by plasmapheresis within 7 days prior to first study drug administration.
10. Individuals who have participated in another clinical trial or who received an investigational drug within 30 days prior to first study drug administration.
11. Females having used implanted, injected, intravaginal, or intrauterine hormonal contraceptive within 6 months prior to first study drug administration.
12. Females taking oral or transdermal hormonal contraceptives within 30 days prior to first study drug administration.
13. Use of any enzyme-modifying drugs or products in the previous 30 days before first study drug administration.
14. Use of any prescription medication within 14 days prior to first study drug administration (except medically acceptable contraceptive products).
15. Use of any over-the-counter medications within 14 days prior to first study drug administration (except for medically acceptable contraceptive products).
16. Consumption of food or beverages containing grapefruit and/or pomelo within 10 days prior to first study drug administration.
17. Consumption of food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing.
18. Individuals having undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by Investigator.
19. Difficulty with swallowing whole film-coated tablet.
20. Women who are pregnant or lactating.
21. Have had a tattoo or body piercing within 30 days prior to first study drug administration.

Primary outcomes:
measure: The maximal observed plasma concentration (Cmax)
timeFrame: Up to 72 hours post dose in each treatment period
measure: Area under the concentration-time curve from time zero to 72 hours (AUC72)
timeFrame: Up to 72 hours post dose in each treatment period
measure: Area under the concentration-time curve from time zero to infinity (AUCinf)
timeFrame: Up to 72 hours post dose in each treatment period
measure: Time when the maximal plasma concentration is observed (Tmax)
timeFrame: Up to 72 hours post dose in each treatment period
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: BioPharma Services Inc.
state: Ontario
Study officials:
affiliation: BioPharma Service Inc.
name: Isabella Szeto, MD, CCFP
role: PRINCIPAL_INVESTIGATOR
References: